Disruption of the blood–brain and blood–spinal cord barriers (BBB and BSCB, respectively)
and immune cell infiltration are early pathophysiological hallmarks of multiple sclerosis (MS)…

Objective: Blood‐derived myeloid antigen‐presenting cells (APCs) account for a significant
proportion of the leukocytes found within lesions of multiple sclerosis (MS) and experimental …

Growing evidence supports a role for IL-1 in multiple sclerosis and experimental autoimmune
encephalomyelitis (EAE), but how it impacts neuroinflammation is poorly understood. We …

Activated leukocyte cell adhesion molecule (ALCAM) is a cell adhesion molecule found on
blood–brain barrier endothelial cells (BBB-ECs) that was previously shown to be involved in …

The migration of circulating leukocytes into the central nervous system (CNS) is a key driver
of multiple sclerosis (MS) pathogenesis. The monoclonal antibody natalizumab proved that …

Objective Although Tc17 lymphocytes are enriched in the central nervous system (CNS) of
multiple sclerosis (MS) subjects and of experimental autoimmune encephalomyelitis (EAE) …

Molecular interventions that limit pathogenic CNS inflammation are used to treat autoimmune
conditions such as multiple sclerosis (MS). Remarkably, IL-1β–knockout mice are highly …

The blood–brain barrier (BBB) constitutes an elaborate structure formed by specialized capillary
endothelial cells, which together with pericytes and perivascular glial cells regulates the …

In multiple sclerosis, encephalitogenic CD4 + lymphocytes require adhesion molecules to
accumulate into central nervous system inflammatory lesions. Using proteomic techniques, we …

Blood–brain barrier function is driven by the influence of astrocyte-secreted factors. During
neuroinflammatory responses the blood–brain barrier is compromised resulting in central …